Short answer
GRAIL, Inc. (GRAL) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $45M (up 25.7% year over year) with net income of −$110M.
Q2 2026 key financials · XBRL
- Revenue
- $45M
- +25.7% YoY · +9.6% QoQ
- Net income
- −$110M
- +3.3% YoY · −18.3% QoQ
- Operating margin
- -388.9%
- EPS (diluted)
- −$2.57
- +19.2% YoY · −12.2% QoQ
Source: XBRL data from the GRAIL, Inc. (GRAL) Q2 2026 10-Q on SEC EDGAR. USD.
GRAIL, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New securities litigation risk triggered by June 2026 Robbins class action alleging NHS-Galleri trial misstatements
- New governance risk from June 2026 Augitto derivative action alleging fiduciary-duty breaches over NHS-Galleri disclosures
- Regulatory and clinical risk: NHS-Galleri Trial missed its primary endpoint for statistically significant combined Stage 3 and 4 reduction
- Market risk: February 2026 trial announcement caused a next-day stock-price decline
- Shareholder activism risk following adverse NHS-Galleri results, potentially affecting strategy, capital allocation, or governance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GRAIL, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.